Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on April 16, 2008. The filing discloses the approval of the 2008 Senior Executive Incentive Structure and the adoption of a Change in Control Policy by the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation policies and does not contain financial performance data for the period.
Material Changes and Compensation Details
2008 Senior Executive Incentive Structure
- Cash Awards: Tied to stock appreciation. If the stock does not appreciate, there is no cash award pool. If it appreciates, the pool equals a percentage of the increase in adjusted market capitalization (1/100th of the increase, capped at 2% for increases of 200% or more).
- Equity Awards: Maximum stock option grants were established for senior executives, contingent on meeting at least 75% of individual performance criteria.
| Executive Officer | Maximum Stock Option Grant |
|---|---|
| Jonathan E. Lim (President and CEO) | 150,000 |
| David A. Ramsay (CFO) | 40,000 |
| Robert Little (VP, Chief Commercial Officer) | 40,000 |
| Richard Yocum (VP, Clinical Development) | 40,000 |
| Gregory I. Frost (Chief Scientific Officer) | 40,000 |
| William Fallon (VP, Manufacturing and Operations) | 40,000 |
| Matthew Hooper (VP, General Counsel) | 40,000 |
Change in Control Policy
The Board adopted a policy providing benefits for senior executives terminated without cause within 12 months of a change in control:
- Cash Payment: Lump sum equal to 2x base salary for the CEO and 1.5x base salary for other senior executives.
- Healthcare: Continued coverage for 18 months (CEO) or 12 months (other executives).
- Equity Acceleration: Full acceleration of unvested equity awards granted after policy adoption.
- Tax Optimization: Gross payments may be reduced if it results in a greater net payment to the executive after tax considerations.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or specific risk factors beyond the standard disclosure of compensation arrangements. The Board retains flexibility to approve cash and equity awards higher or lower than the calculated amounts.
Key Facts for Investor Verification
- Verify the Company's stock price performance in 2008 to determine the potential size of the cash award pool.
- Confirm the specific individual performance criteria required for executives to receive their maximum equity grants.
- Review future filings for the execution of individual agreements documenting the Change in Control Policy terms.
- Note that the filing contains no operational or financial results; investors should refer to the most recent 10-K or 10-Q for financial health.